NCT03132454 2025-11-03
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
17 trialsNCT03805932 2025-07-24
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT04996160 2025-01-24
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
Stanford University
Phase 1 Recruiting
NCT05476770 2024-12-06
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Recruiting
NCT03349281 2022-10-20
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
University of Miami
Phase 1 Completed
NCT02293109 2022-03-10
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
University of California, Davis
Phase 1 Completed
NCT00866307 2021-04-27
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
Children's Oncology Group
Phase 1 Completed
NCT03515200 2020-09-01
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 1 Terminated
NCT02779283 2020-05-26
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 1 Completed
NCT01363817 2019-07-30
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Bristol-Myers Squibb
Phase 1 Completed
NCT00928200 2019-02-19
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT03591744 2018-12-19
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
City of Hope Medical Center
Phase 1 Withdrawn
NCT00629473 2017-11-22
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies
Celgene
Phase 1 Completed
NCT01324180 2017-08-07
Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01403415 2015-07-10
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01088763 2014-11-05
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00003217 2014-07-25
Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 1 Completed